<DOC>
	<DOCNO>NCT01023542</DOCNO>
	<brief_summary>The primary objective trial evaluate efficacy safety delay introduction ( 30 day post-transplantation patient without sign acute rejection receive aIL-2 induction MMF ) either cyclosporine everolimus versus 5-day delay cyclosporine combination MMF .</brief_summary>
	<brief_title>CNI-free `` Bottom '' -up Immunosuppression Patients Undergoing Liver Transplantation</brief_title>
	<detailed_description>The risk develop chronic renal failure liver transplantation ( LT ) pre-MELD era approximately 20 % 5 year , associate use CNI 4-fold increase mortality risk . Besides pre-transplant factor associate end-stage hepatic disease influence renal function ( hepatorenal syndrome [ HRS ] ) , major risk factor associate early post-transplant renal impairment : preexisting diabetes mellitus , time wait list end-stage hepatic disease , requirement blood product , liver allograft dysfunction , HCV-infection toxicity Calcineurin-inhibitors ( CNI ) ( 1-8 ) . The introduction MELD-based allocation system Eurotransplant area December 2006 lead increase proportion liver transplant recipient renal dysfunction time liver transplantation ( LT ) , since creatinine become key component allocation liver allograft ( 9 ) . Data 2 recent publication indicate incidence pre-transplant renal impairment eGFR ≤ 60ml/min . approximately 50 % . Renal impairment MELD-scores ≥ 24 well requirement renal replacement therapy LT result significantly unfavorable outcome LT ( 10,11 ) . An additional problem specific patient group ( impaired renal function time LT MELD-scores ≥ 25 ) , high risk develop infectious complication ( 12 ) . Studies indicate early infection present almost 85 % patient , become common cause death early transplantation . Notably , two-third infection liver transplant patient occur within first 3 month transplantation high percentage ( 67 % ) severe infection ( 13,14 ) . In general , inflammatory response associate infection impair immunosuppressive drug . This disturbed regulation increase susceptibility broad range normal opportunistic infection ( 15 ) . Therefore , patient high lab-MELD score hypothetically require rather low amount immunosuppressive ( IS ) drug first day week transplantation , state SIRS ( systemic inflammatory response syndrome ) -like state ( 16,17 ) . In Regensburg collective 30 patient renal impairment ( creatinine 1.5 g/dL high and/or eGFR 50 ml/min low ) time point LT , day 1 LT , treat either standard CNI + MMF + basiliximab + steroid ( control-arm ; group 2 ) CNI-free protocol consist MMF + basiliximab + steroid ( treatment-arm ; group 1 ) . Baseline renal function similar : serum creatinine ( SCr ) median 1.8 mg/dL ( 1.5 4.0 mg/dL ) ( group A ) vs. 2.4 mg/dL ( 1.5 4.0 mg/dL ) ( group B ) [ p=0.24 ] . Results retrospective case-control study show cumulative requirement renal replacement therapy significantly low group B ( p=0.032 ) . Ten 15 patient receive additional immunosuppression ( 4 CNI 6 mTOR inhibitor ) beyond day 30 . By month 6 ( 1.3 mg/dL vs. 1.1 mg/dL ) month 12 ( 1.6 mg/dL vs. 1.2 mg/dL ) , group B patient show significantly good SCr ( eGFR ) value group A ( p=0.006 ) . Rates BPAR similar , pulmonary complication higher group A result significantly longer stay ICU ( 9 vs. 21 day ; p=0.04 ) . The investigator conclude collective CNI-free- '' bottom-up '' immunosuppression severely ill patient renal impairment prior LT feasible may innovative approach improve outcome ( 18 ) . Based initial finding investigator initiate prospective uncontrolled two-step pilot-trial investigate safety efficacy CNI-free de novo `` bottom-up '' immunosuppression patient undergo LT exist renal impairment ( PATRON07-study , clinicaltrials.gov-identifier : NCT00604357 ) ( 19 ) . In first step pilot trial , nine patient treat MMF 2x1g i.v./day , include induction therapy basiliximab 20 mg i.v . day 0 4 , center-specific steroid ; sirolimus introduce regimen least 10 day LT . The primary endpoint incidence steroid-resistant biopsy-proven acute rejection 30 day transplantation , early detector safety efficacy . Analysis first nine patient confirm finding retrospective analysis summarize section 2.1 . Only one biopsy proven acute rejection occur . No patient lose allograft , patient die within one year LT. Renal function improve significantly baseline 30 day , 3 6 month transplantation ( p=0.004 ) . At 3 6 month , 72 % patient still CNI-free . All side-effects observe expected treatment mTOR-inhibitors . Although median lab MELD-score baseline 29 ( range : 10 40 ) , initial Karnowsky-index 20 ( range : 10 80 ) , patient recover quite quickly Karnowsky-index 60 ( range : 20 80 ) day 30 80 ( range : 50 100 ) 3 month LT . These finding indicate feasibility CNI-free de novo `` bottom-up '' IS without increase risk acute rejection , graft-loss mortality beneficial impact short- long-term renal function independent risk-factor long-term mortality LT .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>1 . Male female liver transplant recipient primary liver transplant old 18 year 2 . Signed , write informed consent prior randomization 3 . MELD score ≥25 4 . Lack relevant exclusion criterion 1 . Patients transplant autoimmune hepatitis 2 . HIV positive patient 3 . Patients pretransplant immunosuppressive treatment 4 . Patients recipients multiple solid organ islet cell tissue transplant , previously receive organ tissue transplant . 5 . Patients renal failure CKD/ESRD require renal replacement therapy 2 week prior transplantation . 6 . Patients sign hepatic artery thrombosis . 7 . Patients hepatic encephalopathy grade Stadium II , III IV ( somnolence , sopor loss consciousness 8 . Patients know hypersensitivity drug use study class , excipients . 9 . Patients recipient ABO incompatible transplant graft . 10 . Patients uncontrolled therapy refractory hypercholesterolemia ( &gt; 350 mg/dL ; &gt; 9 mmol/L ) hypertriglyceridemia ( &gt; 500 mg/dL ; &gt; 8.5 mmol/L ) time transplantation . 11 . Patients platelet count &lt; 50,000/mm3 time randomization . 12 . Patients absolute neutrophil count &lt; 1,000/mm³ white blood cell count &lt; 2,000/mm³ time randomization . 13 . Patients creatinine/protein ratio indicate daily urinary protein excretion &gt; 1 g/24h time randomization . 14 . Women childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean , UNLESS ( 1 ) meet follow definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/m , ( 2 ) past 6 week surgical bilateral oophorectomy without hysterectomy ( 3 ) use one follow acceptable method contraception : surgical sterilization ( e.g. , bilateral tubal ligation , vasectomy ) , hormonal contraception ( implantable , patch , oral ) , copper coat IUD doublebarrier method ( double combination male female condom spermicidal gel , diaphragm , sponge , cervical cap ) . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Reliable contraception maintain throughout 3 month study drug discontinuation . 15 . Patients history coagulopathy medical condition require longterm anticoagulation would preclude liver biopsy transplantation . 16 . Patients psychologic , familial , sociologic geographic condition potentially hamper compliance study protocol followup schedule . 17 . Patients guardianship ( e.g . individual able freely give informed consent ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>renal impairment</keyword>
	<keyword>MELD &gt; 25</keyword>
	<keyword>Liver transplantation</keyword>
	<keyword>CNI-free</keyword>
	<keyword>Bottom-Up</keyword>
	<keyword>Everolimus</keyword>
</DOC>